CTLA4 and Primary hypothyroidism: Primary hypothyroidism was associated with anti-PD-1 inhibitors; pembrolizumab and nivolumab and with combination anti-PD-1 and CTLA4 inhibitor therapy (nivolumab plus ipilimumab).